Biologic Pathways Involved In Hereditary Angioedema And Response To Ruconest® Treatment during prodrome and attack

Hereditary angioedema (HAE) attacks are associated with a prodrome in ∼ 85% of patients’ pre-attack. The purpose of this study was to determine whether blood transcriptomic changes, pre- and post-treatment of a prodrome with Ruconest® (recombinant human C1-INH), overlapped with changes pre- and post-treatment of an acute attack.